Enhertu reduced risk of disease progression by 72%
18 September 2021 14:05 BST Enhertu reduced the risk of disease progression or death by 72% vs.trastuzumab emtansine (T-DM1) in patients withHER2-positive metastatic breast cancer Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO PresidentialSymposium support Enhertu as the potential new standard of care in previously treated patients DESTINY-Breast01 Phase II trial data also presented at ESMO showed impressive median overallsurvival of 29.1 months in HER2-positive patients following two or more HER2-based regimens Detailed positive results